NASDAQ:AKYA Akoya Biosciences (AKYA) Stock Price, News & Analysis → This AI Trade Machine Made 1,729%* (With 89% Wins) (From Prosper Trading Academy) (Ad) Free akya Stock Alerts $3.80 -0.02 (-0.52%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$3.75▼$3.8450-Day Range$3.80▼$6.0352-Week Range$3.04▼$8.80Volume93,172 shsAverage Volume144,582 shsMarket Capitalization$187.64 millionP/E RatioN/ADividend YieldN/APrice Target$9.07 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Akoya Biosciences alerts: Email Address Akoya Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside138.7% Upside$9.07 Price TargetShort InterestBearish4.74% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 2 Articles This WeekInsider TradingSelling Shares$74,325 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.86) to ($0.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.14 out of 5 starsMedical Sector533rd out of 914 stocksAnalytical Instruments Industry18th out of 26 stocks 3.4 Analyst's Opinion Consensus RatingAkoya Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAkoya Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.74% of the float of Akoya Biosciences has been sold short.Short Interest Ratio / Days to CoverAkoya Biosciences has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Akoya Biosciences has recently increased by 2.19%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAkoya Biosciences does not currently pay a dividend.Dividend GrowthAkoya Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AKYA. Previous Next 2.0 News and Social Media Coverage News SentimentAkoya Biosciences has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Akoya Biosciences this week, compared to 2 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akoya Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,325.00 in company stock.Percentage Held by InsidersOnly 8.50% of the stock of Akoya Biosciences is held by insiders.Percentage Held by Institutions79.42% of the stock of Akoya Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Akoya Biosciences are expected to grow in the coming year, from ($0.86) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akoya Biosciences is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akoya Biosciences is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkoya Biosciences has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Akoya Biosciences Stock (NASDAQ:AKYA)Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.Read More AKYA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKYA Stock News HeadlinesApril 24, 2024 | americanbankingnews.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Receives Average Rating of "Moderate Buy" from BrokeragesApril 22, 2024 | globenewswire.comAkoya to Report First Quarter 2024 Financial Results on May 13th, 2024April 27, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 17, 2024 | americanbankingnews.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Sees Large Decline in Short InterestApril 9, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Akoya Biosciences (AKYA)April 5, 2024 | globenewswire.comAkoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and ScaleMarch 16, 2024 | uk.investing.comAkoya Biosciences CEO sells $37k worth of sharesMarch 9, 2024 | uk.investing.comAkoya Biosciences Inc (AKYA)April 27, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. March 6, 2024 | seekingalpha.comAkoya Biosciences, Inc. (AKYA) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | markets.businessinsider.comMassaro Issues Buy Rating for Akoya Biosciences Amid Strong Financial Performance and Market Growth PotentialMarch 5, 2024 | finance.yahoo.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Q4 2023 Earnings Call TranscriptMarch 5, 2024 | finanznachrichten.deAkoya Biosciences, Inc.: Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial OutlookMarch 5, 2024 | finance.yahoo.comQ4 2023 Akoya Biosciences Inc Earnings CallMarch 4, 2024 | investorplace.comAKYA Stock Earnings: Akoya Biosciences Beats EPS, Beats Revenue for Q4 2023March 4, 2024 | benzinga.comRecap: Akoya Biosciences Q4 EarningsMarch 4, 2024 | msn.comAkoya Biosciences GAAP EPS of -$0.22 beats by $0.06, revenue of $26.5M beats by $0.39MMarch 4, 2024 | finance.yahoo.comAkoya Biosciences Inc (AKYA) Reports Record Q4 Revenue and Sets Positive 2024 OutlookMarch 4, 2024 | globenewswire.comAkoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial OutlookMarch 3, 2024 | markets.businessinsider.comAkoya Biosciences earnings: here's what to expectMarch 1, 2024 | benzinga.comEarnings Outlook For Akoya BiosciencesFebruary 24, 2024 | finance.yahoo.comAkoya Biosciences Insiders Placed Bullish Bets Worth US$2.11mFebruary 22, 2024 | benzinga.comAkoya Biosciences Stock (NASDAQ:AKYA) Insider TradesFebruary 16, 2024 | finance.yahoo.comRNA Mar 2024 12.500 putFebruary 8, 2024 | finance.yahoo.comAkoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor ConferenceFebruary 7, 2024 | finance.yahoo.comStrength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?January 31, 2024 | benzinga.comAkoya Biosciences Stock (NASDAQ:AKYA) Dividends: History, Yield and DatesSee More Headlines Receive AKYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akoya Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/04/2024Today4/27/2024Next Earnings (Confirmed)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:AKYA CUSIPN/A CIK1711933 Webwww.akoyabio.com Phone855-896-8401FaxN/AEmployees330Year FoundedN/APrice Target and Rating Average Stock Price Target$9.07 High Stock Price Target$11.00 Low Stock Price Target$7.50 Potential Upside/Downside+138.7%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,320,000.00 Net Margins-65.53% Pretax Margin-65.49% Return on Equity-110.24% Return on Assets-36.14% Debt Debt-to-Equity Ratio1.41 Current Ratio3.45 Quick Ratio2.94 Sales & Book Value Annual Sales$96.63 million Price / Sales1.94 Cash FlowN/A Price / Cash FlowN/A Book Value$1.10 per share Price / Book3.45Miscellaneous Outstanding Shares49,380,000Free Float45,183,000Market Cap$187.64 million OptionableOptionable Beta1.48 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Brian McKelligon (Age 55)President, CEO & Director Comp: $1.15MMr. John Frederick Ek (Age 48)CFO, Principal Financial Officer & Principal Accounting Officer Dr. Frederic G. Pla Ph.D. (Age 65)Chief Operating Officer Comp: $445.27kPriyam ShahSenior Director of Business Development & Investor Relations StrategyMs. Jennifer Kamocsay (Age 53)General Counsel Dr. Niro Ramachandran Ph.D. (Age 49)Chief Business Officer Comp: $298.18kDr. Pascal Bamford Ph.D.Senior Vice President, Research & Development and Laboratory OperationsMr. Rob C. Hart CFAJ.D., SecretaryMore ExecutivesKey CompetitorsPrelude TherapeuticsNASDAQ:PRLDSutro BiopharmaNASDAQ:STROSeerNASDAQ:SEERAthira PharmaNASDAQ:ATHANautilus BiotechnologyNASDAQ:NAUTView All CompetitorsInsiders & InstitutionsBrian MckelligonSold 7,500 sharesTotal: $37,275.00 ($4.97/share)Brian MckelligonSold 7,500 sharesTotal: $37,050.00 ($4.94/share)Parkman Healthcare Partners LLCBought 149,164 shares on 2/15/2024Ownership: 1.375%Kent Lake Capital LLCSold 629,686 shares on 2/14/2024Ownership: 0.238%CIBC Asset Management IncBought 73,737 shares on 2/13/2024Ownership: 0.236%View All Insider TransactionsView All Institutional Transactions AKYA Stock Analysis - Frequently Asked Questions Should I buy or sell Akoya Biosciences stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akoya Biosciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AKYA shares. View AKYA analyst ratings or view top-rated stocks. What is Akoya Biosciences' stock price target for 2024? 7 equities research analysts have issued 1-year price objectives for Akoya Biosciences' stock. Their AKYA share price targets range from $7.50 to $11.00. On average, they predict the company's stock price to reach $9.07 in the next year. This suggests a possible upside of 138.7% from the stock's current price. View analysts price targets for AKYA or view top-rated stocks among Wall Street analysts. How have AKYA shares performed in 2024? Akoya Biosciences' stock was trading at $4.88 at the start of the year. Since then, AKYA stock has decreased by 22.1% and is now trading at $3.80. View the best growth stocks for 2024 here. Are investors shorting Akoya Biosciences? Akoya Biosciences saw a decline in short interest in March. As of March 31st, there was short interest totaling 988,400 shares, a decline of 5.9% from the March 15th total of 1,050,000 shares. Based on an average daily trading volume, of 203,800 shares, the short-interest ratio is presently 4.8 days. Approximately 4.7% of the company's stock are short sold. View Akoya Biosciences' Short Interest. When is Akoya Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our AKYA earnings forecast. How can I listen to Akoya Biosciences' earnings call? Akoya Biosciences will be holding an earnings conference call on Monday, May 13th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were Akoya Biosciences' earnings last quarter? Akoya Biosciences, Inc. (NASDAQ:AKYA) issued its earnings results on Monday, March, 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.05. The company earned $26.49 million during the quarter, compared to analysts' expectations of $26.12 million. Akoya Biosciences had a negative net margin of 65.53% and a negative trailing twelve-month return on equity of 110.24%. During the same period last year, the business posted ($0.50) earnings per share. What guidance has Akoya Biosciences issued on next quarter's earnings? Akoya Biosciences issued an update on its FY 2024 earnings guidance on Monday, March, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $114.0 million-$118.0 million, compared to the consensus revenue estimate of $117.4 million. When did Akoya Biosciences IPO? Akoya Biosciences (AKYA) raised $125 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 6,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity served as the underwriters for the IPO. How do I buy shares of Akoya Biosciences? Shares of AKYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AKYA) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akoya Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
